SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 145 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,670,612 | +2.4% | 390,538 | +47.6% | 0.02% | -5.3% |
| Q2 2023 | $5,539,020 | -22.8% | 264,645 | -22.1% | 0.02% | -24.0% |
| Q1 2023 | $7,172,183 | +2812520.8% | 339,592 | +3290.8% | 0.02% | +2400.0% |
| Q4 2022 | $255 | -99.9% | 10,015 | -50.2% | 0.00% | -50.0% |
| Q3 2022 | $484,000 | -88.1% | 20,121 | -90.5% | 0.00% | -86.7% |
| Q2 2022 | $4,055,000 | -34.8% | 210,744 | -25.8% | 0.02% | -16.7% |
| Q4 2021 | $6,216,000 | +148.0% | 283,954 | +67.2% | 0.02% | +28.6% |
| Q3 2020 | $2,506,000 | -5.1% | 169,792 | -4.7% | 0.01% | -17.6% |
| Q2 2020 | $2,641,000 | – | 178,192 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |